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Abstract
Background: Gastrointestinal stromal tumors (GIST) are uncommon intra-abdominal tumors.
These tumors tend to present with higher frequency in the stomach and small bowel. In fewer than
5% of cases, they originate primarily from the mesentery, omentum, or peritoneum. Furthermore,
these extra-gastrointestinal tumors (EGIST) tend to be more common in patients greater than 50
years of age. Rarely do EGIST tumors present in those younger than 40 years of age.
Case presentation: We report a case of a large EGIST in a 27-year-old male. An abdominal pelvic
computerized tomography imaging demonstrated an intra-abdominal mass of 22 cm, without
invasion of adjacent viscera or liver lesions. This mass was resected en bloc with its fused omentum
and an adherent portion of sigmoid colon. Pathology results demonstrated a malignant
gastrointestinal stromal tumor with positive CD117 (c-kit) staining, and negative margins of
resection, and no continuity of tumor with the sigmoid colon. Due to the malignant and aggressive
nature of this patient's tumor, he was started on STI-571 as adjuvant chemotherapy.
Conclusion: Stromal tumors of an extra-gastrointestinal origin are rare. Of the reported omental
and mesenteric EGISTs in four published series, a total of 99 tumors were studied. Of the 99
patients in these series only 8 were under 40 years of age, none were younger than 30 years old;
and only 5 were younger than 35 years old. Our patient's age is at the lower end of the age
spectrum for the reported EGISTs. Young patients who present with an extra-gastrointestinal
stromal tumor (EGIST), who have complete resection with negative margins, have a good
prognosis. There is little data to support the role of STI-571 in adjuvant or neoadjuvant therapy
after curative resection. Given the lack of data, the use of STI-571 must be individualized.
Background
Gastrointestinal stromal tumors (GIST) are the most com-
mon mesenchymal tumors of the gastrointestinal tract,
although their overall incidence is low. In the United
States of America, it is estimated that 3,300 to 4,350 new
GISTS are diagnosed every year. It is well accepted that
their cell of origin is the interstitial cell of Cajal. The com-
monality of these tumors is a positive immunohistochem-
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istry stain to CD117 also known as C-kit located at 4q11-
12. Mutations have frequently been identified in exon 11
of the C-kit gene, but also on exons 9 and 13 [1,2]. These
tumors also tend to be positive for CD34 [3]. Tumors pre-
viously diagnosed as gastrointestinal leiomyomas, leio-
myoblastomas, and leiomyosarcomas, as well as tumors
previously deemed neurofibromas or schwannomas [2]
are now re-classified as GISTs based on immunohisto-
chemistry.
Gastrointestinal stromal tumors can appear anywhere in
the gastrointestinal tract, from the mouth to the anus, but
also in extra-gastrointestinal locations such as mesentery,
omentum, peritoneum [4-6]. Gastrointestinal stromal
tumors arise more commonly found in the stomach (40–
70%), small intestine (20–40%), and colon (5–15%).
Omental, mesenteric, and retroperitoneal tumors com-
prise less than 5% [1,2,5,7]. The independent predicting
factors of tumor behavior are tumor size and mitotic activ-
ity [2,5,7-9], but age and location are also predictive fac-
tors [10]. The significance of tumor site in prediction of
malignant behavior is site dependant [7]. Gastrointestinal
stromal tumors are a disease entity predominantly of peo-
ple older than 50 years of age, with adults less than 40
years of age accounting for 5% to 20% [2]. Children
account for less than 3% of GIST [1,11].
Case presentation
We present the case of a 27 years old Caucasian male that
presented to our emergency department with chief com-
plaint of right lower quadrant abdominal pain. The
patient was referred with a 24 hour onset of colicky pain,
of seven of ten in intensity. He denied bowel habit
changes, fevers or chills, but he did complain of nausea,
and postprandial fullness, but no vomiting. There was no
history of weight loss over the last year and he denied any
abdominal trauma or past surgeries. His family history
was significant for colonic cancer in his father at age 47
and breast cancer in his mother at age 60.
Examination showed a well-developed male in no acute
distress with obvious abdominal distension. Abdominal
palpation demonstrated a large mass extending from the
right upper quadrant and epigastrium to the right lower
quadrant. The mass was non-pulsatile, moderately tender,
and non-mobile. No peritoneal signs were appreciated.
His lower extremities showed no edema, and his rectal
examination was negative for masses or gross or micro-
scopic blood in the stools.
A computerized tomography of the abdomen and pelvis
was performed which showed a large ovoid intraabdomi-
nal heterogeneous mass measuring 22 cm in greatest
length extending from the right upper quadrant to the pel-
vis without invasion into adjacent viscera (Fig 1). Chest X-
ray showed no lung parenchyma or bony lesions, and the
CT scan of the abdomen was negative for liver lesions. A
colonoscopy was attempted, but we were unable to pass
the transverse colon due to the extraluminal compression,
but no polyps, lesions or blood were appreciated. Tumor
markers were drawn for CA-19-9, CA-125, beta-HCG, and
alpha-fetoprotein. Only CA-123 was elevated at 128.
The patient was operated for resection of the mass. Upon
gaining access to the peritoneal cavity, a moderate
amount of serosanguinous fluid was evident and collected
for cytology. A "muscular" mass was immediately appar-
ent and occupied most of the peritoneal cavity (Fig 2). The
mass arose from the greater omentum, which was densely
fused to it. On its inferior pole the mass was in close appo-
sition to the sigmoid colon, but was not fused to it.
The mass was removed en block with the greater omentum
and the adjacent sigmoid colon. The margins were sent for
frozen section and came back as negative for malignancy.
Cytology of the peritoneal fluid revealed reactive mes-
othelial cells.
Final pathology showed a malignant gastrointestinal stro-
mal tumor with smooth muscle differentiation and nega-
tive margins of resection. Based on the size of the
neoplasm and necrosis present, in spite of few mitoses,
this tumor was best viewed as a malignant or at least an
aggressive extra-gastrointestinal stromal tumor (Fig 3).
Immunostainings for LCA, CD117, CD34, pancytokera-
tin, s100, smooth muscle actin, calretinin, EMA, vimen-
tin, CEA, LEU M1, and Factor VIII were done. The positive
results included CD 117 (C-Kit), smooth muscle actin and
vimentin (Fig 4). The postoperative period was uncompli-
cated, and medical oncology service was consulted and
the patient was placed on a STI-571 regimen.
Discussion
The extra-gastrointestinal stromal tumors (EGIST) studied
by Miettinen et al., [4] (13 omental and 10 mesenteric)
showed low mitotic activity. They were typically positive
for CD117, but less so for CD34. Like our case, these
EGIST often showed alpha smooth muscle actin reactivity,
but were all negative for desmin and S-100 protein [4].
The reported cases of extra-gastrointestinal stromal
tumors (EGIST) have included omental, mesenteric, and
retroperitoneal tumors. The cellular origin of GIST from
the interstitial cell of Cajal (ICC) raises the question of
whether these EGIST are truly an entity analogous to
GISTs. It is not well known if extra-gastrointestinal stro-
mal tumors (EGIST) originate from pacemaker cells out-
side of the GI tract or if mesenchymal cells have the ability
to recapitulate the phenotype.World Journal of Surgical Oncology 2008, 6:50 http://www.wjso.com/content/6/1/50
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CT images at six different levels demonstrates a large 22 cm intraabdominal mass displacing the small bowel to the left Figure 1
CT images at six different levels demonstrates a large 22 cm intraabdominal mass displacing the small bowel 
to the left.
Intraoperative images show a large mass within the abdomen and the displacement of the small bowel (left) Figure 2
Intraoperative images show a large mass within the abdomen and the displacement of the small bowel (left). 
The mass originated from the greater omentum as can be seen on the right.World Journal of Surgical Oncology 2008, 6:50 http://www.wjso.com/content/6/1/50
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Sakurai et al. [12], published their results on the cytologi-
cal, immunohistochemical, and genetic analysis of 5
omental mesenchymal tumors in 2001. They found all
five tumors to be positive for CD117 and CD34 staining,
while all were negative for smooth-muscle cell markers.
More importantly, the authors reported finding KIT
immunoreactive CD117 and CD34 cells within speci-
mens of omentum [12]. These findings and those of
Yamamoto et al., [13] underscore the fact that histologi-
cally, EGISTs have a similar appearance to GISTs, and that
EGIST is a distinctive entity, different from leiomyosarco-
mas [4]. The most common mutation of the KIT gene
occurred in exon 11 in Sakurai's and Yamamoto's experi-
ence [12,13]. According to Yamamoto [13], only 48% of
his case tumors were positive for c-kit mutation (14 of 29
analyzed specimens). Of the EGISTs lacking detectable c-
kit gene mutations, the author raised the possibility of an
alternative oncogenic mechanism. Rubin et al., [14] dem-
onstrated that, even in GISTs that lacked sequence muta-
tions, KIT was highly phosphorylated.
Mitotic activity, cellularity and presence of necrosis have
been found to be associated with worse outcomes. C-kit
gene mutations were not found to correlate with progno-
sis in patients with EGISTs according to Yamamoto [13].
A high mitotic rate (>5/50 HPF) and a high Ki-67 labeling
index (>10%) had a significantly poorer outcome. Reith et
al. found a mitotic rate of >2/50 HPF, the presence of
necrosis, and high cellularity to be useful in predicting
biologic behavior in EGISTs, which tend to have an
aggressive behavior similar to distal GI tract GISTs [15].
Of the omental EGISTs reported by Yamamoto, Sakurai,
and Miettinen [4,12,13] (total of 28 cases), the mean
diameter of the tumor was 15.35 cm. Only two patients
with omental EGIST were younger than 40 years of age
[4,13]. The follow up of the three patients with omental
EGIST reported by Yamamoto was 6, 62, and 48 months;
all three patients had no evidence of disease at end of fol-
low-up [13]. In Miettinen's series, nine patients were fol-
lowed, of which two died during follow up (one of
Microscopic imaging of the tumor at 10×, 20×, 40× shown with H&E staining Figure 3
Microscopic imaging of the tumor at 10×, 20×, 40× shown with H&E staining.
The tumor showed strong positivity to CD117 staining Figure 4
The tumor showed strong positivity to CD117 staining.World Journal of Surgical Oncology 2008, 6:50 http://www.wjso.com/content/6/1/50
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colonic adenocarcinoma and another of unknown
causes); six were alive and without evidence of disease at
2.34 years; one patient was alive and well at 8.5 years of
follow up [4].
Of the reported omental and mesenteric EGISTs in four
published series a total of 99 tumors were studied
[4,12,13,15]. Of the 99 patients in these series, only 8
were under 40 years of age, none were younger than 30
years old; and only 5 were younger than 35 years old. Our
patient's age is at the lower end of the age spectrum for the
reported EGISTs. Of the 8 under 40 years of age patients
with EGISTs, 6 were females. The youngest patient with an
EGIST that we were able to identify in the literature was a
17 year old female with an abdominal wall EGIST [1].
GISTs are very rare in the pediatric population, but EGIST
are even rarer. Of the 32 patients with omental or
mesenteric EGISTs with follow up reported by Reith, 14
were alive and without evidence of disease with at least
7.5 months of follow up. Nine patients died of their dis-
ease at four months [15].
We achieved an R0 resection in our patient, but given the
size and presence of necrosis in the tumor adjuvant STI-
571 was started. There is no prospective data supporting
the use of STI-571 in an adjuvant or neoadjuvant therapy
after curative resection of GIST or EGIST. Yamamoto et al.
suggests that the application of STI-571 could be a thera-
peutic strategy for EGISTs since they have kit alterations
[13]. Todoroki et al. used STI-571 (300 mg/day orally) as
adjuvant postoperative treatment in a 65-year-old female
with a primary omental stromal tumor after R0 resection
with a disease free follow-up at six months [16]. The
American College of Surgeons Committee on Cancer
(ACOSOG) is currently leading a phase II trial to test the
benefit of adjuvant STI-571 with 400 mg/day for one year
in patients after complete resection of high-risk tumors
primary GISTs. The risk of recurrence after resection of a
primary GIST is high. Conventional chemotherapy has
proven ineffective against GIST (less than 10% response).
The use of adjuvant STI-571 is based on the assumption of
highest impact on residual microscopic disease, despite a
negative margin of resection of the primary tumor [3].
STI-571 has demonstrated favorable response in more
than half of patients with advanced and unresectable or
metastatic GIST [17]. There has been reported resistance
to STI-571 in patients with metastatic or recurrent disease,
to which there are no good therapeutics currently [3].
Conclusion
The existing data on EGIST is not sufficient to make a sig-
nificant conclusion on the prognosis and survival of these
patients, but certainly cellularity, mitosis and necrosis of
the tumor appeared to be a prognostic factor [15]. While
answers to the use of STI-571 in an adjuvant or even neo-
adjuvant setting are found, the management of patients
with GIST or EGIST tumors at high risk of recurrence, such
as ours, will be based on the clinical judgment of the treat-
ing physician and the availability of clinical trials.
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